March 16, 2025 - 04:18

Researchers at Stanford University have revealed alarming findings regarding carbon capture technology, suggesting that investments in this area may be more detrimental than beneficial. The study highlights significant flaws in the current methodologies employed by leading corporations, raising concerns about the effectiveness of these technologies in addressing climate change.
The research indicates that the environmental impact of carbon capture may outweigh its intended benefits. By focusing resources on this technology, companies might be diverting attention and funding away from more sustainable and effective solutions. The researchers argue that the current approach should be reconsidered, emphasizing the need for a shift towards more holistic and environmentally friendly practices.
The implications of this study are profound, urging policymakers and corporate leaders to reevaluate their strategies in combating climate change. As the urgency to address environmental issues grows, the call to abandon ineffective technologies becomes increasingly critical in the quest for a sustainable future.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...